Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI in peer review: the elephant in the editorial room.

Evidence-based dentistry·2026
Same author

Do We Need Systematic Reviews of Research Priority Setting? A Proposal for a New Concept on Conducting Systematic Reviews of Research Priority Setting Exercises.

Cochrane evidence synthesis and methods·2026
Same author

Seeing Anxiety: Ecological Video Ethnography and Simulation to Understand Anxiety and Decision-Making in Dental Care.

Health expectations : an international journal of public participation in health care and health policy·2026
Same author

Evidence-based dentistry: holding the method, widening the conversation.

British dental journal·2026
Same author

A dental-friendly menu? Asking different questions and involving different voices in evidence-based dentistry.

Evidence-based dentistry·2026
Same author

Are we entering a new era of artificial intelligence (AI)-supported decision-making in dentistry?

Evidence-based dentistry·2025

Related Experiment Video

Updated: May 22, 2026

Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis
05:36

Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis

Published on: October 4, 2024

Beta2-adrenoceptor agonists for dysmenorrhoea.

Zbys Fedorowicz1, Mona Nasser, Vanitha A Jagannath

  • 1UKCC (Bahrain Branch), College of Medicine, AMA International University of Bahrain, Awali, Bahrain.. zbysfedo@batelco.com.bh

The Cochrane Database of Systematic Reviews
|May 18, 2012
PubMed
Summary

Beta2-adrenoceptor agonists show unclear effectiveness for primary dysmenorrhoea. Limited studies with high bias risk and significant side effects like nausea and palpitations necessitate caution in their use.

More Related Videos

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

Ex Vivo Method for Assessing the Mouse Reproductive Tract Spontaneous Motility and a MATLAB-based Uterus Motion Tracking Algorithm for Data Analysis
06:22

Ex Vivo Method for Assessing the Mouse Reproductive Tract Spontaneous Motility and a MATLAB-based Uterus Motion Tracking Algorithm for Data Analysis

Published on: September 1, 2019

Related Experiment Videos

Last Updated: May 22, 2026

Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis
05:36

Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis

Published on: October 4, 2024

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

Ex Vivo Method for Assessing the Mouse Reproductive Tract Spontaneous Motility and a MATLAB-based Uterus Motion Tracking Algorithm for Data Analysis
06:22

Ex Vivo Method for Assessing the Mouse Reproductive Tract Spontaneous Motility and a MATLAB-based Uterus Motion Tracking Algorithm for Data Analysis

Published on: September 1, 2019

Area of Science:

  • Gynaecology
  • Pharmacology
  • Clinical Trials

Background:

  • Dysmenorrhoea affects up to 50% of premenopausal women, with 10% experiencing incapacitating pain.
  • Primary dysmenorrhoea lacks identifiable pelvic pathology.
  • Beta2-adrenoceptor agonists have been explored for primary dysmenorrhoea treatment, but their efficacy remains uncertain.

Purpose of the Study:

  • To evaluate the effectiveness and safety of beta2-adrenoceptor agonists in managing primary dysmenorrhoea.

Main Methods:

  • Conducted a systematic search of multiple databases including Cochrane, MEDLINE, EMBASE, and PsycINFO up to August 2011.
  • Included randomized controlled trials comparing beta2-adrenoceptor agonists with placebo or other treatments in women with primary dysmenorrhoea.
  • Two independent reviewers assessed trial quality and extracted data.

Main Results:

  • Five trials with 187 women (aged 15-40) were analyzed, using various beta2-adrenoceptor agonists (isoxsuprine, terbutaline, ritodrine).
  • Heterogeneity across studies prevented data pooling; only one study suggested pain relief with a combination therapy.
  • No significant clinical difference in effectiveness was found between agonists and placebo in other studies, with adverse effects reported in up to 25% of participants.

Conclusions:

  • The current evidence, based on small, biased studies, is insufficient for confident decision-making regarding beta2-adrenoceptor agonists for dysmenorrhoea.
  • Potential benefits must be weighed against a range of significant side effects, including nausea, dizziness, and palpitations.
  • Limitations in data precision and reporting necessitate further high-quality research.